Target intelligence / Profile preview

DNA-directed RNA polymerase I subunit RPA12 (POLR1H)

Target
POLR1H
Molecular classification
Enzyme, DNA-dependent RNA polymerase, Transcription factor (subunit of transcription machinery)
01

Overview

DNA-directed RNA polymerase I subunit RPA12 (POLR1H) is a core component of RNA polymerase I, a DNA-dependent enzyme responsible for synthesizing ribosomal RNA precursors in the nucleolus[4][5]. This subunit contains two zinc-binding motifs and facilitates proofreading during transcription by cleaving misincorporated nucleotides, helping maintain transcription fidelity[4][3]. RNA polymerase I-dependent rRNA synthesis is essential for ribosome biogenesis and cell growth, and dysregulation is linked to cancer and congenital disorders known as ribosomopathies[1][2]. POLR1H participates in regulatory pathways controlling cell proliferation and ribosome production and may influence progression in certain cancers and HIV[3]. As a critical enzymatic subunit necessary for cellular homeostasis, POLR1H and the RNA polymerase I complex are considered promising drug targets, especially for anticancer therapies[2][8].

Other names
RNA polymerase I subunit HPOLR1HRPA12ZNRD1hZR14HTEX-6tctex-6A12.2Zinc ribbon domain-containing protein 1HTEX6Rpa12TCTEX6TEX6ZR14
02

Mechanism of action

Inhibition of RNA polymerase I activity (blocks rRNA synthesis, affecting cell proliferation, especially in cancer cells)[2]

03

Biological functions

Ribosomal RNA synthesisRegulation of cell proliferationProofreading and cleavage of misincorporated ribonucleotidesTranscription fidelity
04

Disease associations

CancerRibosomopathies (e.g., Treacher Collins syndrome, acrofacial dysostosis, hypomyelinating leukodystrophy)Gastric cancerSeckel syndromeHIV progression
05

Safety considerations

Potential impact on normal cellular homeostasis due to critical function in ribosome productionAdverse effects possible from inhibition in non-target tissues due to essential role in cell growth and proliferation[2]
06

Interacting drugs

Small molecule inhibitors of RNA polymerase I (notably in clinical trials for cancer; specific drugs targeting POLR1H subunit not identified in search results, inhibition generally directed at Pol I complex)[2]
07

Biomarkers

Changes in POLR1H expression levels may serve as a biomarker for cancer and ribosome biogenesis disorders[3]

Beyond the preview

Go deeper on DNA-directed RNA polymerase I subunit RPA12 (POLR1H).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA-directed RNA polymerase I subunit RPA12 (POLR1H).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call